维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09887 维立志博-B

未开盘 10-08 16:08:17

45.160

-4.440

-8.95%

最高50.800	最低45.020	成交量237.04万
今开49.520	昨收49.600	日振幅11.65%
总市值89.87亿	流通市值89.42亿	总股本1.99亿
成交额1.11亿	换手率1.20%	流通股本1.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":45.16,"timestamp":1791446897010,"preClose":49.6,"halted":0,"volume":2370402,"delay":0,"changeRate":-0.08951612903225815,"floatShares":198000000,"shares":199000000,"eps":-1.4165001334149516,"marketStatus":"未开盘","change":-4.44,"latestTime":"10-08 16:08:17","open":49.52,"high":50.8,"low":45.02,"amount":111084209,"amplitude":0.116532,"askPrice":45.26,"askSize":100,"bidPrice":45.16,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":-1.6120614394374595,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":49.6,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"volumeRatio":6.289560461801098,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/","defaultTab":"news","newsList":[{"id":"1149540833","title":"维立志博-B 2026年9月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149540833","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149540833?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:52","pubTimestamp":1790931151,"startTime":"0","endTime":"0","summary":"南京维立志博生物科技股份有限公司于2026年10月2日公布《截至2026年9月30日之证券变动月报表》。报告期内，公司法定/注册股本总额为人民币1.99亿元，与上月底相比无变化。公告显示，截至本月末，维立志博-B已发行的普通股H股总数为197,670,289股，未上市股份数量为1,221,511股，两类股份的数量均未发生增减变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140468158","title":"异动解读｜维立志博-B盘中下跌5.24%，报49.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140468158","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140468158?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:53","pubTimestamp":1790905990,"startTime":"0","endTime":"0","summary":"10月2日，维立志博-B盘中下跌5.24%，报49.8港元/股，成交额243.55万港元。维立志博-B所在的生物科技行业整体承压，个股中，百济神州跌6.3%，信达生物跌4.49%，康方生物跌2.85%，三生制药跌5.49%，科伦博泰生物跌5.13%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671210512","title":"港股异动 | 维立志博-B(09887)涨超2% 近日核心产品维利信?获日本孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2671210512","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671210512?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:07","pubTimestamp":1790734021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B涨超2%，截至发稿，涨1.69%，报51.25港元，成交额354.03万港元。　　消息面上，9月28日，维立志博-B发布公告，公司核心产品维利信获日本厚生劳动省授予孤儿药资格认定，用于治疗肺外神经内分泌癌。这些激励措施将有望加速维利信在日本的开发、注册及商业化进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260930/32384932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","09887","VXUS","BK4588","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671269420","title":"港股公告掘金 | 罗博特科、景旺电子等4只新股今日上市 广汽拟发行A股收购一汽丰田50%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269420","media":"智通财经","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269420?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:59","pubTimestamp":1790643578,"startTime":"0","endTime":"0","summary":"【重大事项】广汽集团(02238)拟收购一汽丰田50%股权一汽股份将成为第二大股东网龙(00777)与九州订立备忘录，成立及营运合营集团以及建议发行认股权证中远海能(01138)向子公司上海LNG增资17亿元 打造绿色低碳、产业链协同的专业运输能力维立志博-B(09887)核心产品维利信获日本孤儿药资格认定诺比侃(02635)拟折让约13.61%配股净筹约1.315亿港元商汤-W(00020)授出","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300757","600026","02238","BK4604","BK1535","BK1526","LU1993786604.SGD","LU1960683339.HKD","BK4099","BK4585","BK1104","BK1179","BK1110","BK1531","LU1807302812.USD","LU1023057109.AUD","BK1519","00053","BK1116","06731","BK1610","LU0307460666.USD","BK1170","GULRY","LU0359201612.USD","LU0588546209.SGD","LU0880133367.SGD","TM","00020","03750","BK4555","BK1615","SG9999014674.SGD","BK1109","BK4588","HK0000252160.HKD","00331","01138","LU0359201885.HKD","BK1166","00777","601238","03160","LU1008478684.HKD","LU1152091754.HKD","BK1148","03228","BK1230","LU1152091168.USD","BK1539","02635","LU0067412154.USD","300750","HK0000500386.USD","LU0359202008.SGD","603650","80020","03757","603228","BK1119","BK1161","BK1183","HK0000252152.HKD","09607","09887","BK1613"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145561593","title":"维立志博-B核心产品维利信获日本MHLW孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1145561593","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145561593?lang=zh_cn&edition=full","pubTime":"2026-09-28 12:16","pubTimestamp":1790568978,"startTime":"0","endTime":"0","summary":"2026年9月28日，南京维立志博生物科技股份有限公司发布自愿公告称，其核心产品维利信获日本厚生劳动省授予孤儿药资格认定，用于治疗肺外神经内分泌癌。这是继美国食品药品监督管理局和欧盟委员会之后，维利信取得的第三项孤儿药资格认定。获批后，维利信将在日本享受临床开发资金补助、MHLW专业指导、优先咨询及优先审评通道、费用减免以及再审查期延长等政策激励，预计将加速该产品在日本的开发、注册及商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670470740","title":"维立志博新任CBO履历引争议","url":"https://stock-news.laohu8.com/highlight/detail?id=2670470740","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670470740?lang=zh_cn&edition=full","pubTime":"2026-09-27 12:45","pubTimestamp":1790484333,"startTime":"0","endTime":"0","summary":"近日，一则Biotech药企的高管任命消息在医药圈掀起波澜。9月23日，南京维立志博生物科技股份有限公司（简称“维立志博”或“公司”，9887.HK）宣布任命杜文胜为首席商务官（CBO），并介绍其加入前曾任恒瑞医药（600276.SH）全球商务拓展副总裁，期间牵头与多家跨国药企及领先生物技术公司达成多项BD交易，为恒瑞全球化战略创造了重要价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609273884439577.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609273884439577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000500386.USD","BK1161","HK0000252152.HKD","09887","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670475577","title":"持续单边下跌的维立志博-B(09887)，正距离下一轮行情的关键转折点越来越近？","url":"https://stock-news.laohu8.com/highlight/detail?id=2670475577","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670475577?lang=zh_cn&edition=full","pubTime":"2026-09-26 14:07","pubTimestamp":1790402871,"startTime":"0","endTime":"0","summary":"近期，维立志博-B核心品种维利信在国际学界备受关注。因此，维立志博股价何时兑现利好，成为现阶段投资者关注的焦点。但若后续公司盘面出现连续的放量阳线，或许将成为预示维立志博股价接下来终止本轮单边下跌趋势的重要信号。如果市场对维立志博的定价节奏依旧保持\"预期先行、落地兑现\"的话，那现阶段或许距离其下一轮行情的关键转折点正越来越近，而其中的关键催化因素，便是2026 ESMO年会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105244384","title":"异动解读｜维立志博-B盘中下跌5.6%，生物科技板块整体走弱叠加近期剧烈波动后获利回吐延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1105244384","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105244384?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:48","pubTimestamp":1790214488,"startTime":"0","endTime":"0","summary":"9月24日，维立志博-B盘中下跌5.6%，报53.05港元/股，成交额2373.68万港元。消息面上，生物科技板块整体承压，康方生物跌3.13%、荣昌生物跌4.57%、云顶新耀跌4.28%，板块情绪低迷。个股层面，公司近日围绕ESMO突破性摘要入选及股份激励平台南京礼至以均价63.69港元减持约85.91万股等事件剧烈波动，9月22日跌5.59%、23日涨5.54%，短期获利回吐压力再度释放。此外，公司中期净亏损约2.22亿元，同比扩大33.38%，基本面仍处亏损阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技板块走弱，维立志博承压下挫","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150006290","title":"异动解读｜维立志博-B盘中上涨5.54%，ESMO突破性摘要入选叠加前日超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1150006290","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150006290?lang=zh_cn&edition=full","pubTime":"2026-09-23 13:11","pubTimestamp":1790140312,"startTime":"0","endTime":"0","summary":"9月23日，维立志博-B盘中上涨5.54%，报57.15港元/股，成交额6776.29万港元。消息面上，公司此前公告核心产品维利信单药治疗晚期肺外神经内分泌癌的关键注册性IIb期研究入选ESMO最新突破摘要，并获优选口头报告展示资格，将于10月26日进行展示，标志着该研究具备重大临床价值。前一交易日股价曾因股份激励平台南京礼至以均价63.69港元减持约85.91万股引发获利回吐，单日下跌5.59%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博ESMO摘要入选，股价强势反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186271672","title":"异动解读｜维立志博-B盘中下跌5.59%，股份激励平台减持叠加获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1186271672","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186271672?lang=zh_cn&edition=full","pubTime":"2026-09-22 09:40","pubTimestamp":1790041233,"startTime":"0","endTime":"0","summary":"9月22日，维立志博-B盘中下跌5.59%，报53.9港元/股，成交额1859.45万港元。消息面上，公司股份激励平台南京礼至于9月15日以均价63.69港元场内减持约85.91万股，涉资约5471.64万港元，减持后好仓比例由15.37%降至14.93%。尽管公司同日晚间公告维利信单药治疗晚期EP-NEC的关键注册性IIb期研究入选ESMO 2026最新突破摘要并获优选口头报告资格，但此前股价已因大摩上调评级至\"增持\"及WCLC数据催化连续反弹，短期获利回吐压力显现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维立志博盘中走低，激励平台减持引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669016976","title":"维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4–1BB双抗)单药治疗晚期EP-NEC的关键注册性IIB期研究入选LBA，以及三项研究获优选口头报告展示资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2669016976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669016976?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:18","pubTimestamp":1790000312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，在欧洲肿瘤内科学会年会2026年周年大会(2026 ESMO)， 本公司自主研发的在研药物维利信(奥帕替苏米单抗，PD-L1/4–1BB双抗)单药治疗晚期肺外神经内分泌癌(“EP-NEC)的关键注册性IIB期临床研究，已入选最新突破摘要(LBA)，并获优选口头报告展示资格，标志着有关研究具备突破性创新性质与重大临床价值，其研究结果有望改变现有临","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","HK0000500386.USD","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199959551","title":"维立志博-B三项研究获ESMO 2026优选口头报告 关键IIb期数据被列为突破性摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=1199959551","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199959551?lang=zh_cn&edition=full","pubTime":"2026-09-21 22:15","pubTimestamp":1790000143,"startTime":"0","endTime":"0","summary":"2026年9月21日，南京维立志博生物科技股份有限公司发布自愿公告称，旗下在研双特异性抗体维利信单药用于晚期肺外神经内分泌癌的关键注册性IIb期研究入选2026年欧洲肿瘤内科学会年会“最新突破摘要”，并获得优选口头报告展示资格。官方日程显示，该口头报告将于2026年10月26日当地时间上午10时15分至10时25分进行展示。2026年7月，其创新生物制品上市申请被NMPA纳入优先审评审批程序，并于8月正式受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103284956","title":"维立志博-B：Xiaoqiang Kang减持，好仓比例降至14.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103284956","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103284956?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:41","pubTimestamp":1789983713,"startTime":"0","endTime":"0","summary":"Xiaoqiang Kang于2026年9月15日在联交所场内以每股均价63.6904港元卖出维立志博-B股份85.91万股，涉资约5471.64万港元，属场内主动交易，即在二级市场直接买卖股份。此次减持源于礼至合伙根据员工指示出售股份，Kang Xiaoqiang本人并未减持个人持股。Xiaoqiang Kang此次减持前持有维立志博-B好仓3037.59万股，占比15.37%；减持后持股量为2951.68万股，好仓比例降至14.93%。本次涉及关联方：Lai Shoupeng。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199500707","title":"维立志博-B：南京礼至企业管理谘询中心（有限合伙）减持，好仓比例降至14.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199500707","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199500707?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:21","pubTimestamp":1789982475,"startTime":"0","endTime":"0","summary":"维立志博-B的股份激励平台之一南京礼至企业管理谘询中心于2026年9月15日在联交所场内以每股均价63.6904港元卖出85.91万股股份，涉资约5471.64万港元。该笔交易属场内主动交易，即在二级市场直接买卖股份，系根据公司员工指示出售其各自归属的股份。礼至合伙此次减持前持有维立志博-B好仓3037.59万股，占比15.37%；减持后持股量为2951.68万股，好仓比例降至14.93%。本次涉及关联方：Kang Xiaoqiang、Lai Shoupeng、LeadsTech Limited、引领生物有限公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191469692","title":"异动解读｜维立志博-B盘中上涨5.29%，大摩上调评级叠加WCLC数据催化延续反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1191469692","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191469692?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:45","pubTimestamp":1789955112,"startTime":"0","endTime":"0","summary":"9月21日，维立志博-B盘中上涨5.29%，报58.7港元/股，成交额2229.34万港元。此前里昂亦维持116.9港元目标价及\"跑赢大市\"评级。公司于9月14日在WCLC以口头报告形式发布维利信联合化疗一线治疗NSCLC的II期更新数据，整体ORR达71.0%，非鳞状PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。公司正积极推进维利信一线NSCLC的III期临床布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维立志博-B获大摩上调评级，盘中上涨引关注","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668950248","title":"大行评级丨大摩：上调维立志博目标价至93港元，评级升至“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2668950248","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668950248?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:55","pubTimestamp":1789635304,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668953934","title":"港股异动 | 维立志博-B(09887.HK)午前涨超6% PD-L1/4-1BB双抗于WCLC更新重点数据 LBL-024国内即将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2668953934","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668953934?lang=zh_cn&edition=full","pubTime":"2026-09-17 11:35","pubTimestamp":1789616154,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","09887","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144405437","title":"异动解读｜维立志博-B盘中上涨5.55%，WCLC数据发布后连续回调两日迎来反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1144405437","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144405437?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:05","pubTimestamp":1789610758,"startTime":"0","endTime":"0","summary":"消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，整体ORR达71.0%，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%，安全性良好。数据发布后股价经历两个交易日连续回调，从高点65.75港元累计下跌超18%，呈典型\"利好兑现\"走势，今日出现技术性反弹。此外，里昂此前将公司目标价上调至116.9港元并维持\"跑赢大市\"评级，公司正积极推进维利信一线治疗NSCLC的III期临床布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"WCLC数据亮眼，维立志博-B反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164373426","title":"异动解读｜维立志博-B盘中下跌6.04%，WCLC数据公布后股价延续回调态势","url":"https://stock-news.laohu8.com/highlight/detail?id=1164373426","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164373426?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:07","pubTimestamp":1789524473,"startTime":"0","endTime":"0","summary":"9月16日，维立志博-B盘中下跌6.04%，报53.65港元/股，成交额4594.73万港元，延续前一交易日冲高回落走势。消息面上，公司于9月14日在WCLC世界肺癌大会以口头报告形式发布核心产品维利信联合化疗一线治疗NSCLC的II期临床更新数据，非鳞状NSCLC PD-L1阳性亚组ORR达81.8%、DCR达100%。然而前一交易日股价在高开至65.75港元后即大幅回落跌超6%，呈现典型的\"利好兑现\"走势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"维立志博WCLC数据落地，股价延续回调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667618110","title":"维立志博（09887）冲高回落跌超6% 于WCLC 2026公布维利信II期更新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2667618110","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667618110?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:52","pubTimestamp":1789440763,"startTime":"0","endTime":"0","summary":"金吾财讯 | 维立志博-B 港股早盘高开低走，最高涨到65.75港元，最新跌6.42%，报57.6港元，成交额2.63亿港元。消息面上，维立志博-B发布公告，在2026年世界肺癌大会以口头报告形式发布自主研发的在研药物维利信联合化疗一线治疗非小细胞肺癌患者的II期临床研究更新资料。根据更新资料，展现出前所未有的高缓解率，在鳞状NSCLCPD-L1阴性和阳性患者中观察到几乎完全一致的临床获益，而非鳞状NSCLCPD-L1TPS≥1%患者可获得深度且持久的肿瘤缓解。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991622","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.1324},{"period":"1month","weight":-0.2866},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.5091},{"period":"1year","weight":-0.4284},{"period":"ytd","weight":-0.1145}],"compareEarnings":[{"period":"1week","weight":-0.0336},{"period":"1month","weight":-0.0605},{"period":"3month","weight":-0.0161},{"period":"6month","weight":-0.0814},{"period":"1year","weight":-0.1134},{"period":"ytd","weight":-0.072}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京维立志博生物科技股份有限公司是一家主要从事发现、开发和商业化治疗肿瘤、自身免疫性疾病以及其他严重疾病的新疗法的中国公司。该公司的主要候选药物包括LBL-024、LBL-034、LBL-033、LBL-007等。该公司的LBL-024主要用于治疗肺外神经内分泌癌（EP-NEC）、小细胞肺癌（SCLC）、胆道癌（BTC）及非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、肝细胞癌（HCC）、胃癌（GC）及其他实体瘤。该公司还开发了专有技术平台，包括LeadsBody平台（CD3 T-cell engager平台）、X-body平台（4-1BB engager平台）以及其他几个双特异性抗体及融合蛋白平台。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"维立志博-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维立志博-B,09887,维立志博-B股票,维立志博-B股票老虎,维立志博-B股票老虎国际,维立志博-B行情,维立志博-B股票行情,维立志博-B股价,维立志博-B股市,维立志博-B股票价格,维立志博-B股票交易,维立志博-B股票购买,维立志博-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维立志博-B(09887)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维立志博-B(09887)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}